wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36326096-78E9BEEB-32E6-4B31-8061-2B77498F57D4
Q36326096-78E9BEEB-32E6-4B31-8061-2B77498F57D4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36326096-78E9BEEB-32E6-4B31-8061-2B77498F57D4
Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada
P2860
Q36326096-78E9BEEB-32E6-4B31-8061-2B77498F57D4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36326096-78E9BEEB-32E6-4B31-8061-2B77498F57D4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
3d84deef6aa738ee38d5e4be4c59b94f953bc3d2
P2860
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.